Home › Compare › CGXYY vs ABBV
CGXYY yields 3.21% · ABBV yields 3.06%● Live data
📍 CGXYY pulled ahead of the other in Year 2
Combined, CGXYY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGXYY + ABBV for your $10,000?
China Galaxy Securities Co., Ltd. provides various financial services in the People's Republic of China. Its Securities Brokerage segment offers securities dealing and broking; margin financing to margin clients; and securities lending services. The Company's Futures Brokerage segment is involved in futures dealing and broking, futures information consulting, and training activities. Its Proprietary Trading and Other Securities Trading Services segment engages in trading of equities, bonds, funds, derivatives, and other financial products. The Company's Investment Banking segment provides corporate financial services, including equity and debt securities underwriting, and financial advisory services to institutional clients. Its Asset Management segment offers portfolio management, investment advisory, and transaction execution services. The Company's Private Equity and Alternative Investment segment provides equity investments in private companies. Its Overseas Business segment offers securities and futures brokerage, securities research, investment banking, margin financing, money lending, asset management, and insurance brokerage services. The company serves various individual and institutional clients comprising multinational corporations, medium and small-sized enterprises, high-net-worth clients, and retail clients. As of December 31, 2021, it operated through a network of 37 branch offices and 501 securities branches. The company was incorporated in 2007 and is headquartered in Beijing, the People's Republic of China. China Galaxy Securities Co., Ltd. operates as a subsidiary of China Galaxy Financial Holdings Company Limited.
Full CGXYY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.